Literature DB >> 11733726

In vivo damage of CNS myelin and axons induced by peroxynitrite.

T Touil1, M S Deloire-Grassin, C Vital, K G Petry, B Brochet.   

Abstract

In multiple sclerosis (MS) the mechanisms of injury caused by peroxynitrite remain uncertain. To study histological, ultra structural and molecular alterations caused by peroxynitrite in brain, the peroxynitrite donor 3-morpholinosydnonimine was injected in rat corpus callosum. Peroxynitrite induces strong primary axonal damage with characteristics of primary acute axonopathy, together with severe myelin alteration, myelin vacuolation and demyelination, and nitrotyrosine formation as confirmed by detection of nitrosated target proteins. Administration of the peroxynitrite scavenger uric acid inhibited these effects. In vivo, peroxynitrite leads to a disorganisation of myelin and to axonal damage presenting some similarities to the formation of MS lesions. Understanding the action of peroxynitrite in this process will open new therapeutic strategies by specific inhibition of peroxynitrite formation and action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733726     DOI: 10.1097/00001756-200111160-00052

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

Review 1.  Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Authors:  Ludwig Kappos; Jens Kuhle; Achim Gass; Lutz Achtnichts; Ernst-Wilhelm Radue
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Nitric oxide and multiple sclerosis.

Authors:  Juan Manuel Encinas; Louis Manganas; Grigori Enikolopov
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

3.  pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Authors:  David Kremer; Joel Gruchot; Vivien Weyers; Lisa Oldemeier; Peter Göttle; Luke Healy; Jeong Ho Jang; Yu Kang T Xu; Christina Volsko; Ranjan Dutta; Bruce D Trapp; Hervé Perron; Hans-Peter Hartung; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

Review 4.  Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies.

Authors:  Klaus G Petry; Bruno Brochet; Vincent Dousset; Jean Rodolphe Vignes; Claudine Boiziau
Journal:  J Neural Transm (Vienna)       Date:  2010-06-23       Impact factor: 3.575

Review 5.  The influence of nutritional factors on the prognosis of multiple sclerosis.

Authors:  Gloria von Geldern; Ellen M Mowry
Journal:  Nat Rev Neurol       Date:  2012-10-02       Impact factor: 42.937

6.  Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.

Authors:  A L Guerrero; F Gutiérrez; F Iglesias; J Martín-Polo; S Merino; J I Martín-Serradilla; E Laherrán; M A Tejero
Journal:  Neurol Sci       Date:  2011-02-16       Impact factor: 3.307

Review 7.  Remyelination in PNS and CNS: current and upcoming cellular and molecular strategies to treat disabling neuropathies.

Authors:  Sedigheh Momenzadeh; Mohammad-Saeid Jami
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

Review 8.  Lipoic Acid and Other Antioxidants as Therapies for Multiple Sclerosis.

Authors:  Carin Waslo; Dennis Bourdette; Nora Gray; Kirsten Wright; Rebecca Spain
Journal:  Curr Treat Options Neurol       Date:  2019-05-06       Impact factor: 3.598

9.  A comparative evaluation of the response to peroxynitrite by a brain endothelial cell line and control of the effects by drug targeting.

Authors:  Christopher Bolton; Elizabeth G Wood; Gwen S Scott; Roderick J Flower
Journal:  Cell Mol Neurobiol       Date:  2009-03-28       Impact factor: 5.046

Review 10.  Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020.

Authors:  Niklas Huntemann; Leoni Rolfes; Marc Pawlitzki; Tobias Ruck; Steffen Pfeuffer; Heinz Wiendl; Sven G Meuth
Journal:  Drugs       Date:  2021-06-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.